03320 CHINARES PHARMA
- 5.890
- +0.310+5.56%
CHINARES PHARMA News
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
華潤醫藥：公告有關於中國發行中期票據及公司債券的華潤醫藥控股截至2024年3月31日止三個月的未經審核財務業績
China Resources Pharmaceutical (03320.HK): Jiangzhong Pharmaceutical's net profit of 267 million yuan in the first quarter increased 9.99% year-on-year
Gelonghui, April 29丨China Resources Pharmaceutical (03320.HK) announced that Jiangzhong Pharmaceutical (600750.SH) achieved operating income of 1,227 billion yuan in the first quarter of 2024, down 8.74% year on year; net profit attributable to shareholders of listed companies (Jiangzhong Pharmaceutical) was 267 million yuan, up 9.99% year on year; net profit attributable to shareholders of listed companies (Jiangzhong Pharmaceutical) after deducting non-recurring profit and loss was 264 million yuan, up 16.64% year on year.
華潤醫藥：公告江中藥業截至2024年3月31日止三個月的未經審核財務業績
Express News | China Stem Cell Group signs contract with China Resources Pharmaceutical Commercial Group to complement each other's strengths and promote transformation of results
China Resources Pharmaceutical (03320.HK): Donga Ejiao's net profit of 353 million yuan in the first quarter increased 53.43% year-on-year
Gelonghui, April 26 | China Resources Pharmaceutical (03320.HK) announced that Donga Ejiao (000423.SZ)'s revenue for the first quarter of 2024 was 1,453 billion yuan, up 35.95% year on year; net profit attributable to shareholders of listed companies (Donga Ejiao) was 353 million yuan, up 53.43% year on year; net profit attributable to shareholders of listed companies (Donga Ejiao) after deducting non-recurring profit and loss was 329 million yuan, up 54.79% year on year; basic earnings per share were 0.5488 yuan.
華潤醫藥：公告東阿阿膠截至2024年3月31日止三個月的未經審核財務業績
華潤醫藥：公告華潤雙鶴截至2024年3月31日止三個月的未經審核財務業績
華潤醫藥：2023年年報
China Resources Pharmaceuticals (03320.HK): Zheng Guiyu Appointed as Secretary and Authorized Representative
Gelonghui, April 24, 丨 China Resources Pharmaceutical (03320.HK) announced that Su Yaofeng has resigned as company secretary since April 24, 2024 and will no longer act as an authorized representative of the company as stipulated in the Hong Kong Stock Exchange Limited securities listing rules. The board of directors is pleased to announce that Zheng Guiyu has been appointed as company secretary and authorized representative with effect from April 24, 2024.
Sinopharm Taiji and China Resources Pharmaceutical Commercial Group signed a strategic cooperation agreement
On April 21, Sinopharm Taiji and China Resources Pharmaceutical Commercial Group signed a strategic cooperation agreement. Yu Min, general manager of Sinopharm Taiji, suggested that the two sides seek channels from the product level, find products from the channel level, jointly build a multi-product, omni-channel, and digital integrated marketing platform, and continuously deepen and promote a close strategic partnership with all aspects and levels.
China Resources Pharmaceutical (03320): China Resources Liberal Arts Biotech's net profit for the first quarter of 152.2 million yuan decreased by 12.97% year-on-year
China Resources Pharmaceuticals (03320) announced that China Resources Biotech, a subsidiary of the company, will be 3 as of March 31, 2024...
華潤醫藥：公告華潤博雅生物截至2024年3月31日止三個月的未經審核財務業績
China Resources Pharmaceuticals (03320.HK): China Resources's net profit to mother was 1,364 billion yuan in the first quarter, up 18.49% year-on-year
Gelonghui, April 22丨China Resources Pharmaceutical (03320.HK) announced that China Resources 39 (000999.SZ) achieved operating income of 7.294 billion yuan in the first quarter of 2024, up 14.82% year on year; net profit attributable to shareholders of China Resources 39 billion yuan, up 18.49% year on year; net profit attributable to China Resources 39 shareholders after deducting non-recurring profit and loss was 1,328 billion yuan, up 17.38% year on year; basic earnings per share were 1.39 yuan.
華潤醫藥：公告華潤三九截至2024年3月31日止三個月的未經審核財務業績
華潤醫藥：公告昆藥集團截止2024年3月31日止三個月的未經審核財務業績
China Resources Pharmaceuticals (03320.HK) completed the proposed internal restructuring involving China Resources Zizhu
Gelonghui, April 18, 丨 China Resources Pharmaceutical (03320.HK) announced the proposed internal restructuring of China Resources Zizhu Pharmaceutical Co., Ltd. (“China Resources Zizhu”). The board of directors is pleased to announce that the share transfer registration with the relevant counterpart department of the State Administration of Market Supervision and Administration has been completed. Therefore, as of the announcement date, according to the terms of the share transfer agreement, Beijing Pharmaceutical has completed a transaction to transfer 100% of China Resources Zizhu's interests to China Resources Shuanghe.
China Resources Pharma Unit Issues 3 Billion Yuan Bonds
China Resources Pharmaceutical Group (HKG:3320) said its unit CR Pharmaceutical Commercial sold 3 billion yuan of bonds in China, according to a Wednesday filing with the Hong Kong Exchange. Two varie
China Resources Pharmaceuticals (03320): China Resources Pharmaceuticals commercially issues no more than 3 billion yuan of corporate bonds
Zhitong Finance App News, China Resources Pharmaceutical (03320) announced that China Resources Pharmaceutical has issued the first issue of 2024 corporate bonds in China, with an issuance scale of no more than RMB 3 billion. The coupon interest rate for corporate bond type 1 is 2.45%, and the term is three years. The coupon interest rate for corporate bond type 2 is 2.63%, and the term is five years. The funds raised from the issuance of this issue of bonds will mainly be used to repay interest-bearing debts.
China Aerospace Science and Technology Group signed a strategic cooperation agreement with China Resources Pharmaceutical Commercial Group Medical Devices Co., Ltd.
Gelonghui, April 14 | According to China Aerospace Science and Technology Corporation, recently, the Beijing Precision Electromechanical Control Equipment Research Institute of the First Academy of China Aerospace Science and Technology Group signed a strategic cooperation agreement with China Resources Pharmaceutical Commercial Group Medical Devices Co., Ltd. The two sides will give full play to their respective advantages and resource accumulation to jointly promote the construction of a highland for the domestic high-end medical equipment industry. According to the content of the cooperation, the two sides will actively explore diverse cooperation models in medical device product development and marketing system establishment, etc., so that each other's technical resources and market resources resonate at the same frequency, further accelerate the transformation of technological achievements, quickly establish marketing and sales channels, and exert
Analysis
Price Target
No Data
